LG Chem 
Welcome,         Profile    Billing    Logout  
 40 Products   109 Diseases   40 Products   37 Trials   1902 News 


12345678910111213...1920»
  • ||||||||||  Besivo (besifovir) / Gilead, LG Chem, Ildong, Vemlidy (tenofovir alafenamide) / Gilead
    Retrospective data, Journal:  Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-na (Pubmed Central) -  Jun 13, 2024   
    In the sensitivity analyses, 48-week VR from randomized-controlled trials were compiled, and the same trend toward the superiority of TDF over ETV was found (OR, 1.51; p = 0.030). Four high-genetic barrier NAs were compared, and TDF was more likely to achieve a VR after 48 weeks, while ETV provided a superior BR after 48 weeks.
  • ||||||||||  Gemiglo (gemigliptin) / Sanofi, LG Chem
    Gemigliptin Attenuates TGF- (Poster Hall (West A4-B2); 392) -  May 20, 2024 - Abstract #ADA2024ADA_2400;    
    In addition, TGX, with no structural resemblance to purine base, does not affect the pyrimidine metabolism and its related kidney toxicity in mice. These results indicate that gemigliptin has the potential to confer protective effects against TGF-?-induced renal fibrosis by elavating FGF21 expression levels in the cultured human proximal tubular epithelial cells.
  • ||||||||||  Hyruan Plus (sodium hyaluronate) / LG Chem
    Journal:  Hyaluronic Acid Viscosupplement Modulates Inflammatory Mediators in Chondrocyte and Macrophage Coculture via MAPK and NF-?B Signaling Pathways. (Pubmed Central) -  May 20, 2024   
    In this study, we examined the impact of hyaluronic acid (HA) viscosupplement, particularly Hyruan Plus, on chondrocytes and macrophages...HA also reduced the expression level of inflammatory cytokines such as IL-1?, TNF-?, and IL-6 in macrophages, and HA exerted an overall protective effect by partially suppressing the MAPK pathway in chondrocytes and p65/NF-?B signaling in macrophages. Therefore, HA shows potential as a viscosupplement for treating arthritic joints.
  • ||||||||||  LG00034053 / LG Chem
    Trial completion, Trial completion date, Trial primary completion date:  A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA (clinicaltrials.gov) -  May 3, 2024   
    P1/2,  N=74, Completed, 
    Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Mar 2024 --> Dec 2023
  • ||||||||||  Review, Journal:  Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. (Pubmed Central) -  Apr 28, 2024   
    Other combination therapies include pembrolizumab (targeting programed cell death protein 1) and axitinib (a VEGFR and PDGFR blocker) or lenvatinib (a multikinase inhibitor). Since the KEYNOTE-426 clinical trial, the use of immune checkpoint inhibitors in combination with protein-tyrosine kinase inhibitors is now the standard of care for most patients with metastatic renal cell carcinomas and monotherapies are used only in those individuals who cannot receive or tolerate immune checkpoint inhibitors.
  • ||||||||||  Gemiglo (gemigliptin) / Sanofi, LG Chem
    Preclinical, Journal:  Improvement effect of gemigliptin on salivary gland dysfunction in exogenous methylglyoxal-injected rats. (Pubmed Central) -  Apr 17, 2024   
    Overall, gemigliptin protected the salivary gland cells from ROS-mediated cell death, reduced the accumulation of amylase and mucins in the salivary glands, and enhanced the salivary function by upregulating aquaporin 5 expression, and it exerted protective effects against MGO-induced salivary gland dysfunction by enhancing the anti-glycation, antioxidant, and salivary secretion activities. Our findings suggest gemigliptin as a potential therapeutic for patients with salivary gland dysfunction caused by the complications of diabetes.
  • ||||||||||  AV-380 / LG Chem
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia (clinicaltrials.gov) -  Apr 4, 2024   
    P1,  N=30, Recruiting, 
    Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027 Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Nov 2024 --> Jul 2025
  • ||||||||||  tigulixostat (LC350189) / LG Chem
    Trial completion, Trial completion date:  A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (clinicaltrials.gov) -  Mar 22, 2024   
    P1,  N=30, Completed, 
    This real-world cohort study confirmed that the biosimilar of ETN, LBEC0101, was comparable to the reference product in terms of continuation rate, effectiveness at initiation of introduction, and effect persistence before and after switching in clinical practice. Not yet recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
  • ||||||||||  Besivo (besifovir) / Gilead, LG Chem, Ildong, Vemlidy (tenofovir alafenamide) / Gilead
    Retrospective data, Journal, Head-to-Head:  Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Na (Pubmed Central) -  Mar 15, 2024   
    The absolute value of the 95% confidence interval for the difference (-0.04 to 0.12) satisfied the a priori limit of a noninferiority of 0.15. : BSV is noninferior to TAF in terms of VR, and their clinical outcomes are comparable to CHB.
  • ||||||||||  pinometostat (EPZ-5676) / Ipsen, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    A systems biology approach for identifying targetable vulnerabilities in Ewing sarcoma (Section 36) -  Mar 5, 2024 - Abstract #AACR2024AACR_7569;    
    Our results are the first report of gemigliptin effect on EPC viability and morphology. These systems biology approaches can identify non-oncogene encoded vulnerabilities in Ewing sarcoma and hold the potential for expanding the number of therapeutic options for tumors driven by untargetable oncoproteins.
  • ||||||||||  GEN-001 / Genome & Company
    Journal:  Profiling of endogenous metabolites and changes in intestinal microbiota distribution after GEN-001 (Lactococcus lactis) administration. (Pubmed Central) -  Feb 28, 2024   
    Compared with predose, the relative abundance (%) of Parabacteroides and Alistipes significantly decreased, whereas that of Lactobacillus and Lactococcus increased; Lactobacillus and tryptophan levels were negatively correlated. A single administration of GEN-001 shifted the gut microbiota in healthy volunteers to a more balanced state as evidenced by an increased abundance of beneficial bacteria, including Lactobacillus, and higher levels of the metabolites that have immunogenic properties.
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem, Tecentriq (atezolizumab) / Roche
    Enrollment open, Trial completion date, Trial primary completion date:  IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov) -  Feb 20, 2024   
    P1/2,  N=29, Recruiting, 
    A single administration of GEN-001 shifted the gut microbiota in healthy volunteers to a more balanced state as evidenced by an increased abundance of beneficial bacteria, including Lactobacillus, and higher levels of the metabolites that have immunogenic properties. Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Dec 2024 | Suspended --> Recruiting
  • ||||||||||  Shinbaro (GCSB-5) / GC Biopharma, LG Chem
    Review, Journal:  Efficacy of herbal medicine in hand osteoarthritis: A narrative review. (Pubmed Central) -  Jan 30, 2024   
    However, there is a lack of strong evidence supporting their effectiveness in hand osteoarthritis (HOA). This emphasizes the potential benefits that these herbs may have for HOA patients.
  • ||||||||||  Gemiglo (gemigliptin) / Sanofi, LG Chem
    Preclinical, Journal:  Gemigliptin Improves Salivary Gland Dysfunction in D-Galactose-Injected Aging Rats. (Pubmed Central) -  Jan 23, 2024   
    In sum, gemigliptin was shown to improve D-gal-induced decline in the salivary gland function of aged rats through its anti-glycation and antioxidant activities. Gemigliptin shows promise as a treatment strategy for patients experiencing decreased salivary function associated with their advancing age.
  • ||||||||||  Gemiglo (gemigliptin) / Sanofi, LG Chem
    Gemigliptin alleviates succinate induced ER stress and activation of hepatic stellate cells (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_1916;    
    This study showed the involvement of ER stress in the activation of succinate-induced LX-2 HSCs and gemigliptin significantly reduced ER stress in HSC activation. Therefore, gemigliptin may become an anti-fibrotic agent and targeting to succinate and ER stress may be a promising therapeutic in the management of liver fibrosis.
  • ||||||||||  Review, Journal:  Pipeline Therapies for Gout. (Pubmed Central) -  Dec 22, 2023   
    A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study...Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.